Back to search results

First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Acute Myeloid Leukemia, Adult · Myelodysplastic Syndromes

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Hôpital de la Timone, Marseille, France, France

    Contact: Study coordinator (Régis COSTELLO) · regis.costello@ap-hm.fr

  • Hôpital Saint-Louis, Paris, France, France

    Contact: Study coordinator (Lina BENAJIBA) · lina.benajiba@aphp.fr

  • Centre Hospitalier Lyon Sud, Pierre-Bénite, France, France

    Contact: Study coordinator (Maël HEIBLIG) · mael.heiblig@chu-lyon.fr
Study leads

  • Laurent BASSET

    Study Director

    Advanced BioDesign

View source on ClinicalTrials.gov(opens in a new tab)